There is a story on the front page of the financial review today, about director remuneration for poor returns. First example is Ian Dunstan.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025